COVID-19 Bivalent Booster Megastudy

Not Applicable

Completed

• Conditions: COVID-19

• Registration Number: NCT05607082
• Lead Sponsor: University of Pennsylvania

Brief Summary

This megastudy is a massive randomized controlled trial. By randomizing participants to 10 different intervention conditions simultaneously, the investigators will be able to compare the effectiveness of different interventions to one another and to a control group (in which individuals will only receive the usual communications from their partner organization) to identify which interventions significantly increase vaccination rates. Pharmacy customers will be randomly assigned to receive one of the interventions designed by team scientists to encourage vaccination or to a control group. The baseline intervention will be based on the top-performing SMS intervention identified in the investigators previous megastudies on encouraging vaccination (Milkman et al., 2021b, 2022). Pharmacy customers will receive SMS messages conveying that a COVID booster vaccine is reserved or waiting for them at the pharmacy. Additional behavioral science messaging strategies will be tested by building off of this baseline intervention.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-11-03
• Study First Submitted: 2022-11-03
• Study First Submitted QC: 2022-11-03
• Study First Posted: 2022-11-07
• Primary Completion: 2022-12-08
• Study Completion: 2023-02-06
• Status Verified: 2023-03
• Last Update Submitted: 2023-03-01
• Last Update Posted: 2023-03-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2600000

Inclusion Criteria

• Patient of a large retail pharmacy that has opted into receving SMS messages from the pharmacy and has received their primary COVID vaccination series.

Exclusion Criteria

• The patient unsubscribed from texts before the send date and time of the patient's SMS/MMS message
• The patient received a bivalent COVID booster before the send date and time of the patient's SMS/MMS message.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Patient uptake of the COVID bivalent booster	During the 30 days after receiving the SMS/MMS intervention	Whether patients receive a bivalent COVID booster at the pharmacy in question

Secondary Outcome Measures

Name	Time	Method
Patient uptake of the COVID bivalent booster	90 days after receiving the SMS/MMS intervention	Whether patients receive a bivalent COVID booster at the pharmacy in question

Trial Locations

Locations (1)

University of Pennsylvania; 🇺🇸 Philadelphia, Pennsylvania, United States